Hematopoietic stem cells (HSCs) are responsible for the life-long maintenance and regeneration of the adult vertebrate blood system. HSCs are generated through a natural transdifferentiation process occurring in specialized embryonic vascular cells, known as hemogenic endothelial cells (ECs \[HECs\]). In mice, the first adult HSCs are generated in the aorta-gonad-mesonephros (AGM) region at embryonic day (E) 10.5 ([@bib31]; [@bib30]). The emergence of the definitive hematopoietic system in the mouse embryo correlates with the temporal appearance of clusters of hematopoietic cells (HCs) associated with the aortic endothelium and the major arteries ([@bib12]; [@bib32]; [@bib10]). Chick embryo dye-marking studies were the first to show that aortic ECs give rise to HCs ([@bib16]). In mammalian embryos, the results of phenotypic and genetic studies, supported by stringent in vivo transplantation studies of enriched cell fractions, demonstrate that HSCs are derived from vascular ECs during a short window of developmental time ([@bib11]; [@bib33]; [@bib57]; [@bib7]). This developmental process is known as endothelial to hematopoietic cell transition (EHT).

To facilitate the study of HSC emergence in the mouse embryo, numerous markers have been used individually and/or in combination to identify HSCs and their direct precursors. Immunolocalization of these markers in the AGM highlighted the heterogeneous nature of the cells in the hematopoietic clusters ([@bib34]; [@bib47]; [@bib53]; [@bib41]). Whereas combinations of these markers allow HSC enrichment, so far no combination of endothelial and/or hematopoietic markers has been able to distinguish hemogenic from nonhemogenic aortic ECs.

The *Ly6aGFP* (Sca1) mouse model, in which all HSCs throughout development are GFP^+^ ([@bib11]; [@bib25]), has facilitated the study of EHT. Clear proof of EHT was obtained by real-time imaging of the mouse *Ly6aGFP* embryonic aorta ([@bib5]). In the E10.5 aorta, at the time when the number of hematopoietic clusters peak ([@bib53]), flat endothelial GFP^+^ cells were observed to transition to morphologically round GFP^+^ cells that begin to express other HSC markers ([@bib5]). Real-time imaging of transgenic zebrafish embryos similarly revealed the transition of aortic ECs to HCs ([@bib3]; [@bib20]), indicating that EHT is an evolutionarily conserved process by which the definitive hematopoietic system of vertebrates is generated.

To specifically understand the molecular program involved in EHT, we set out in this study to identify key genes and processes that are functionally relevant in mouse aortic HECs as they transit to HSCs. Based on the vital imaging of EHT, the *Ly6aGFP* reporter is currently the most tractable marker to distinguish and enrich the HECs that are undergoing EHT from other aortic ECs, and also the emerging HSCs from other HCs. Here we present RNA sequencing data obtained from highly enriched small numbers of relevant EHT cells from *Ly6aGFP* embryos, aortic ECs, HECs, and emerging HSCs. Among the few (530) differentially expressed genes (DEGs) during EHT, *Gpr56* is the highest up-regulated gene encoding a cell surface receptor. We show for the first time the functional involvement of Gpr56 in HSC emergence during EHT. In addition, the previously described "heptad" transcription factors (TFs; [@bib52]) are up-regulated during EHT, bind the Gpr56 enhancer, and regulate its expression. This unique dataset expands our understanding of EHT, identifying the gene networks and processes that are essential for HSC generation in the embryo.

RESULTS
=======

Temporal-spatial and transcriptomic quantitation of aortic hemogenic endothelial and emerging HCs
-------------------------------------------------------------------------------------------------

Ly6aGFP expression marks HCs emerging from hemogenic endothelium at the time of HSC generation in the midgestation mouse aorta. To quantify and localize these cells, we performed confocal imaging of whole and sectioned immunostained E10 *Ly6aGFP* embryos ([Fig. 1, A--D](#fig1){ref-type="fig"}). CD31 marks all ECs and HCs, and cKit marks all HCs. However, Ly6aGFP marks only some ECs and some HCs. High-resolution imaging of transverse sections allowed quantitation of four different Ly6aGFP-expressing aortic cell types ([Fig. 1 D](#fig1){ref-type="fig"}): flat ECs, bulging cells in the single layer of endothelium, and two differently positioned round cells within the clusters distinguished by the close attachment to (juxtaposed) or a position distal from the endothelium. The total number of GFP^+^ cells increased from 287 at early E10 (32 sp \[somite pairs\]) to 1,592 at late E10 (37 sp; [Fig. 1 D](#fig1){ref-type="fig"}). From the small fraction of ECs that express GFP (range 13--19%), most aortic GFP^+^ cells are flat ECs with only 8% of GFP^+^ cells in hematopoietic clusters. Although by a random distribution more GFP^+^ cluster cells would be expected in distal positions (as compared with juxtaposed), we observed 70--88% of the GFP^+^ HCs localized in a juxtaposed position, most likely because GFP^+^ HCs are emerging from GFP^+^ ECs and/or are actively maintained at the juxtaposed position.

![**Analysis of EHT cell subsets.** (A) Whole-mount image of a 34-sp *Ly6aGFP* embryo showing expression of CD31 (magenta), cKit (red), and GFP (green). The aorta, vitelline artery, and somatic vasculature are indicated. (B) Four types of aortic cells during EHT in a *Ly6aGFP* AGM section (36 sp) stained with anti-CD31 (magenta) and anti-cKit antibodies (red). ECs are CD31^+^cKit^−^GFP^−^, HECs are CD31^+^cKit^−^GFP^+^, HSCs are CD31^+^cKit^+^GFP^+^, and HCs are CD31^+^cKit^+^GFP^−^. (C) Transverse section through a 36-sp *Ly6aGFP* embryo showing expression of CD34 (red) and GFP (green). A hematopoietic cluster with some GFP^+^ cells is located ventrally. GFP^+^ ECs are scattered throughout the aorta. (D) Different GFP^+^ cell types (arrowheads) in an E10.5 *Ly6aGFP* aorta. (Endothelial) two flat GFP^+^ ECs; (bulging) rounding-up of a GFP^+^ EC; (juxtaposed) round HC closely adhering to an EC; (distal) round HC on the distal side of the cluster. The number of cells/aorta is listed below at the 32-, 34-, and 37-sp stages. Bars: (A) 100 µm; (B and D) 10 µm; (C) 50 µm. (E) Scatter plot showing the distribution and sorting gates for EHT subsets EC, HEC, HSC, and HC from E10.5/E11 *Ly6aGFP* AGMs. (F) Hematopoietic progenitor numbers (total CFU-C \[CFU-culture\]) per AGM. EHT subsets from E10.5 *Ly6aGFP* AGMs (34--39 sp) were plated in methylcellulose, and colonies were counted at day 12 (SD is shown; *n* = 4). (G) HSC long-term repopulating activity in E11 *Ly6aGFP* AGM EHT subsets (40--49 sp). Irradiated adult recipients (*n* = 4) were injected with 5--9 ee of ECs, 4--9 ee of HECs, 1--5 ee of HSCs, and 4--8 ee of HCs together with 2 × 10^5^ spleen cells (recipient type). Percentage of donor cell chimerism at 4 mo after injection is shown. Indicated above each bar is the number of repopulated recipients/number of recipients injected. (H) Normalized number of mapped fragments for genes encoding the markers used for sorting EHT fractions. FPKMs of *CD31*, *cKit*, and *Ly6aGFP* per fraction are shown (error bars are SD). (I) Heat map of FPKMs for genes encoding several relevant cell surface molecules: *Cdh5*, *Tek*, *Esam*, *Kdr*, and *Eng* in each of the sequenced cell fractions and the frequency of cells in each sorted fraction expressing the corresponding protein. Significant positive correlation is observed between FACS and RNAseq data (*r*^2^ = 0.54; \*\*, P = 0.01).](JEM_20140767_Fig1){#fig1}

Because all HSCs are GFP^+^ and rare HCs have been observed to emerge from GFP^+^ ECs, Ly6aGFP is the best marker for high enrichment of HECs. Hence, we developed an enrichment method using the Ly6aGFP, cKit, and CD31 markers: ECs (CD31^+^cKit^−^GFP^−^), HECs (CD31^+^cKit^−^GFP^+^), HSCs (CD31^+^cKit^+^GFP^+^), and progenitor/differentiated HCs (CD31^+^cKit^+^GFP^−^; [Fig. 1 B](#fig1){ref-type="fig"}). The distinct cell types were sorted ([Fig. 1 E](#fig1){ref-type="fig"}) and hematopoietic function was assessed. Hematopoietic progenitors were found in the HC (64%) and HSC (33%) fractions as expected, with a majority of the immature progenitors (CFU-GEMM) in the HSC fraction ([Fig. 1 F](#fig1){ref-type="fig"}). In vivo transplantation assays revealed that only the CD31^+^cKit^+^GFP^+^ fraction contained HSCs ([Fig. 1 G](#fig1){ref-type="fig"}). These HSCs provided long-term high-level multilineage repopulation of adult irradiated recipients ([Fig. S1 A](http://www.jem.org/cgi/content/full/jem.20140767/DC1){#supp1}; 6 engrafted of 10 injected with 1--5 ee \[embryo equivalents\]). Despite injection of high embryo equivalents of cells from the other fractions (4--9 ee), no repopulation was found with the ECs, HECs, or HCs.

RNA sequencing and validation
-----------------------------

Sorted ECs, HECs, HSCs, and HCs from three independent biological replicates were used for RNA sequencing. As few as 4--14 E10.5 AGM equivalents (34--41 sp) of sorted cells per replicate were obtained, and cDNA was made from as few as 593 sorted cells (see [Table S1](http://www.jem.org/cgi/content/full/jem.20140767/DC1){#supp2} for details). The sequence reads of EHT cell fractions were mapped to the mouse genome (NCBI build 37/mm9), and the generated count table (with 7--57 million unique mapped reads to exons per sample) was normalized and analyzed by *edgeR* ([Fig. 2 A](#fig2){ref-type="fig"}; [@bib28]).

![**RNAseq data analysis.** (A) Distribution of raw counts per sample (left) and *edgeR* internal normalized counts (right). The normalized counts are used in all subsequent analyses. Datasets for three biological replicates are shown for ECs, HECs, HSCs, and HCs. Biological replicate 1 includes two 36-sp and two 37-sp embryos; replicate 2 includes four 34-sp, two 35-sp, three 36-sp, and five 37-sp embryos; replicate 3 includes two 35-sp, one 36-sp, two 38-sp, one 39-sp, one 40-sp, and one 41-sp embryos. (B) BCV in RNAseq samples from three biological replicates of relevant EHT cell fractions: EC, HEC, and HSC. (C) Venn diagram showing numbers of DEGs in comparisons of HECs versus ECs, HSCs versus HECs, and HSCs versus ECs. Total DEGs is 530 (see [Table S2](http://www.jem.org/cgi/content/full/jem.20140767/DC1){#supp3} for gene lists). (D) Heat maps showing all 530 DEGs and hierarchical clustering of the genes in each EHT cell fraction from the three biological replicates.](JEM_20140767_Fig2){#fig2}

To confirm that the transcriptome analysis was representative of the sorted EHT fractions, we measured the normalized number of fragments (in FPKMs \[fragments per kilobase exon reads per million fragments mapped\]) of *CD31*, *cKit*, and *Ly6a* ([Fig. 1 H](#fig1){ref-type="fig"}). As expected, *CD31* transcripts were found in all four subsets (ECs, HECs, HSCs, and HCs), *cKit* transcripts were found only in HCs and HSCs, and *Ly6a* transcripts were found in HECs and HSCs.

Gene transcript reads for endothelial genes *Cdh5*, *Tek*, *Esam*, *Kdr*, and *Eng* were highest in HECs as compared with ECs and were higher in HSCs than in ECs or HCs. When the four cell fractions were examined by FACS ([Fig. 1 I](#fig1){ref-type="fig"}), cell surface expression correlated significantly with transcript levels (r^2^ = 0.54, P = 0.01). Thus, our datasets reflect a dynamic transcriptional program during EHT.

Global transcriptional differences between the EHT cell subsets
---------------------------------------------------------------

Biological coefficient of variation (BCV) analysis indicates ([Fig. 2 B](#fig2){ref-type="fig"}) that EC, HEC, and HSC fractions are closely related but distinct. EC, HEC, and HSC replicate 2 and 3 samples cluster together, whereas replicate 1 EC, HEC and HSC samples show a similar BCV pattern but are further dispersed in the plot. The tighter sample dispersion of replicates 2 and 3 is most likely the result of the higher sequencing depth (Table S1). Hence, distinct transcriptional variation between the EHT fractions is consistent for the three biological replicates.

Dataset comparisons showed a total of 530 DEGs (false discovery rate \[FDR\] \< 0.05; [Fig. 2 C](#fig2){ref-type="fig"} and [Table S2](http://www.jem.org/cgi/content/full/jem.20140767/DC1){#supp4}). The EC to HEC comparison shows 139 DEGs, whereas 340 genes were differentially expressed between HECs and HSCs. Moreover, comparison of ECs with HSCs identified 108 additional genes. MA plots of differential expression analysis show most genes being centered around zero, further confirming the correct normalization of datasets ([Fig. S2 A](http://www.jem.org/cgi/content/full/jem.20140767/DC1){#supp5}). In the EC to HEC comparison, most DEGs are up-regulated, whereas a majority of the DEGs in HEC to HSC are down-regulated. Hierarchical clustering of DEGs grouped the three biological replicates of each fraction together, suggesting that ECs, HECs, and HSCs have recognizably distinct genetic programs ([Fig. 2 D](#fig2){ref-type="fig"}).

Transcriptome analysis reveals processes involved in EHT
--------------------------------------------------------

DEGs were grouped based on their relative expression levels (H, high; I, intermediate; and L, low expression) into representative patterns for EC genes (HIL, HLL, HHL, and HLI), HEC genes (LHL, IHL, IHI, and LHI), and HSC genes (LHH, LIH, IIH, LLH, and ILH; [Fig. 3](#fig3){ref-type="fig"} and Table S2). Each group was used as input for Gene Ontology (GO), KEGG, and WikiPathways enrichment analysis, and Gene Set Enrichment Analysis (GSEA) was used to detect global shifts of gene sets during each transition.

![**GO terms/processes enriched in EHT subsets.** (A) DEG patterns that are EC specific are shown (left): high-intermediate-low (HIL), HHL, HLI, and HLL. GO enrichment analysis was performed using WebGestalt, and enriched GO terms are summarized by REVIGO (right). (B) DEG patterns that are HEC specific are shown (left): LHL, IHL, IHI, and LHI. GO enrichment analysis and GO terms are summarized by REVIGO (right). (C) DEG patterns that are HSC specific are shown (left): LHH, LIH, IIH, LLH, and ILH. GO enrichment and GO terms are summarized by REVIGO. Rectangle size represents the number of DEGs in the accompanying GO term. See [Table S3](http://www.jem.org/cgi/content/full/jem.20140767/DC1){#supp6} for enriched ontology terms.](JEM_20140767_Fig3){#fig3}

EC genes show overrepresentation of "focal adhesion," "ECM-receptor interaction," "protein digestion and absorption," "oxidative stress," and "chemokine signaling" terms ([Fig. 3 A](#fig3){ref-type="fig"} and [Table S3](http://www.jem.org/cgi/content/full/jem.20140767/DC1){#supp7}), consistent with EC function ([@bib38]). Significant enrichment of "inflammatory response" and "TGFbeta signaling" terms suggests ECs to be activated. Whether this is caused by activated endothelium in an actual inflammatory response or by the activation of inflammatory genes that are involved in other signaling pathways in development ([@bib35]; [@bib36]) requires further study.

HEC genes are most enriched in "cell adhesion" and "migration" gene sets, consistent with changes required for HECs to move out of the endothelial layer and form clusters of HCs ([Fig. 3 B](#fig3){ref-type="fig"} and Table S3). Like ECs, 169 out of 191 genes within the "angiogenesis" GO term (GO:0001525) were present in HECs. HEC genes also showed enrichment in "cardiovascular system development," most likely because of the presence of many angiogenic and vascular development genes. Indeed, only 3 (*Jag1*, *Sox17*, and *Fbn1*) out of the 76 published essential cardiovascular genes ([@bib49]) are present in HEC genes. "Delta-Notch" and "Notch" pathways known to be important for HSC generation and cluster formation ([@bib22]) were enriched, and whole transcriptome comparisons using GSEA also show Notch pathway gene sets as up-regulated in HECs ([Fig. 4 A](#fig4){ref-type="fig"} and Fig. S2 B). In addition, multiple "VEGF" and "hypoxia-regulated" gene sets were enriched in HECs as compared with HSCs and ECs ([Fig. 4 A](#fig4){ref-type="fig"}), including *Hif1α*, which was recently shown to be an important factor for HSC generation ([@bib15]). Surprisingly, several previously published HSC gene sets (from MSigDB database v4.0) are significantly enriched in HECs as compared with ECs, whereas no significant enrichment of these genes was found in HSCs as compared with HECs, indicating that the hematopoietic program is already activated in HECs ([Fig. 4 A](#fig4){ref-type="fig"}).

![**Changing processes and cell surface molecules during EHT.** (A) GSEA for VEGF, Notch, Hypoxia up-regulated genes, genes specifically expressed in HSCs, stem cell function--related gene sets like "telomere lengthening" and "DNA repair," cell cycle--related gene sets, and early hematopoietic progenitor--specific genes. (B) Receptor-related genes with significant expression changes in EC to HEC and HEC to HSC transitions. Blue, increased expression; red, decreased expression; gray font, genes with low overall expression levels as defined by edgeR-calculated logCPM of \<3 (and higher probability of being false positive); asterisks, genes differentially expressed during both transitions; logFC, log fold change.](JEM_20140767_Fig4){#fig4}

HSC genes showed clear overrepresentation of "hematopoietic processes," "cell cycle," and "histone methylation" related genes ([Fig. 3 C](#fig3){ref-type="fig"}). Significant enrichment of "cell cycle progression," "DNA replication," and "hematopoietic progenitor" sets was also detected by GSEA ([Fig. 4 A](#fig4){ref-type="fig"} and Fig. S2 C). "Hematopoietic progenitor" gene sets are enriched in HSCs as compared with HECs, and detection of "acute myeloid leukemia" from the KEGG database and "pluripotency network" from WikiPathways is in agreement with the acquisition of hematopoietic fate and self-renewal capacity in HSCs (Table S3). This is further supported by significant enrichment of gene sets characteristic of stem cells, such as "telomere lengthening" and "DNA repair," in the HSC fraction by GSEA ([Fig. 4 A](#fig4){ref-type="fig"}; [@bib55]; [@bib42]).

TF expression in cells undergoing EHT
-------------------------------------

The genetic program directing cell identity is coordinated by TFs, and thus we focused our attention on these genes in our EHT datasets. As compared with ECs, significant up-regulated expression of *Mecom*, *Notch1* and *4*, *Gfi1*, *Sox17*, *Ets2*, and *Elk3* was found in HECs ([Table 1](#tbl1){ref-type="table"}), with *Sox7*, *Sox18*, *Runx1*, *Hhex*, and *Lmo2* among the top up-regulated HEC TFs ([Table S4](http://www.jem.org/cgi/content/full/jem.20140767/DC1){#supp8}).

###### 

Differentially expressed TFs

  HECs versus ECs                       HSCs versus HECs   HSCs versus ECs                                                              
  ------------------------------------- ------------------ ----------------- ------------ ------- --------- ------------------ -------- ---------
  **(A) Top 25 up-regulated genes**                                                                                                     
  *Elk3*                                2.42               1.1E-02           *Myb*        4.23    1.7E-06   *Myb*              4.55     7.1E-08
  *Mecom*                               3.21               1.4E-02           *Gfi1b*      5.48    7.7E-05   *Ikzf2*            3.13     2.5E-04
  *Notch4*                              5.41               2.9E-02           *Hlf*        7.03    8.9E-05   *Hlf*              5.99     6.7E-04
  *Notch1*                              2.16               4.2E-02           *Meis1*      2.20    8.1E-04   *Runx1*            2.68     1.8E-03
  *Rab11a*                              2.03               5.2E-02           *Zfp106*     2.43    3.5E-03   *Myc*              2.27     9.5E-03
  *Gfi1*                                7.69               6.8E-02           *Ncoa4*      2.05    8.8E-03   *Dnmt3a*           1.73     2.2E-02
  *Wwtr1*                               3.20               6.8E-02           *Nop2*       2.35    1.9E-02   *Chd4*             1.62     2.9E-02
  *Junb*                                4.90               6.8E-02           *Elf1*       2.51    2.0E-02   *Dnmt1*            1.58     3.2E-02
  *Ets2*                                2.50               6.9E-02           *Zfp445*     2.05    2.3E-02   *Gfi1*             8.33     3.3E-02
  *Mapk3*                               1.62               7.3E-02           *Nfe2*       5.05    4.1E-02   *Zfp445*           1.91     4.6E-02
  *Nkx2-3*                              5.95               7.4E-02           *Zfp763*     4.29    4.2E-02   *Setbp1*           2.78     5.9E-02
  *Ldb2*                                2.30               7.5E-02           *Ikzf2*      1.94    5.2E-02   *Ikzf1*            2.60     6.8E-02
  *Hdac7*                               2.20               7.6E-02           *Huwe1*      1.55    5.7E-02   *Bcor*             2.21     8.4E-02
  *Sox17*                               5.14               8.4E-02           *Orc2*       2.22    6.5E-02   *Trp53bp1*         1.51     8.5E-02
  *Ctnnb1*                              1.28               9.5E-02           *Mpl*        2.84    6.6E-02   *Mycn*             2.57     9.9E-02
  *[Hey1]{.ul}*                         4.24               1.1E-01           *Etv6*       1.99    6.9E-02   *Zfp106*           1.67     1.0E-01
  *[Epas1]{.ul}*                        3.10               1.2E-01           *Lmo1*       8.87    7.5E-02   *[Suz12]{.ul}*     1.57     1.1E-01
  *[Hey2]{.ul}*                         4.35               1.2E-01           *Paxip1*     1.93    7.6E-02   *[Cbfa2t3]{.ul}*   2.63     1.2E-01
  *[Sox7]{.ul}*                         4.27               1.5E-01           *Cpsf6*      1.28    8.1E-02   *[Paxip1]{.ul}*    1.83     1.4E-01
  *[Sox18]{.ul}*                        4.05               1.5E-01           *Zfp748*     2.68    8.3E-02   *[Notch1]{.ul}*    1.72     1.4E-01
  *[Tsc22d1]{.ul}*                      1.46               1.6E-01           *Polr1a*     2.41    8.3E-02   *[Etv6]{.ul}*      1.82     1.5E-01
  *[Nrarp]{.ul}*                        3.76               1.7E-01           *Trp53bp1*   1.42    8.9E-02   *[Kdm5a]{.ul}*     1.38     1.5E-01
  *[Nfic]{.ul}*                         2.07               1.8E-01           *Dnmt1*      1.29    9.4E-02   *[Meis1]{.ul}*     1.22     1.8E-01
  *[Pdlim1]{.ul}*                       1.96               2.1E-01           *Med23*      1.84    9.8E-02   *[Rreb1]{.ul}*     1.49     1.8E-01
  *[Hmg20b]{.ul}*                       2.46               2.1E-01           *Krr1*       1.45    1.0E-01   *[Bptf]{.ul}*      1.17     1.8E-01
  **(B) Top 25 down-regulated genes**                                                                                                   
  *Pou5f1*                              −7.70              2.6E-04           *Snai2*      −7.39   7.7E-05   *Snai2*            −8.64    3.0E-06
  *Utf1*                                −8.22              1.0E-02           *Id3*        −3.87   5.6E-04   *Rhox6*            −10.09   2.9E-05
  *Gfi1b*                               −3.77              1.3E-02           *Hey2*       −7.55   2.3E-03   *Rhox9*            −10.23   4.6E-05
  *Foxd1*                               −10.54             6.6E-02           *Rhox6*      −6.49   6.8E-03   *Tgfb1i1*          −5.76    4.6E-05
  *Lmo1*                                −10.20             6.7E-02           *Msx2*       −8.54   7.4E-03   *Pou5f1*           −7.16    2.2E-04
  *Hand1*                               −6.55              7.4E-02           *Rhox9*      −6.56   9.0E-03   *Etv5*             −3.26    6.0E-04
  *Zfp612*                              −7.77              1.0E-01           *Etv5*       −2.60   1.1E-02   *Utf1*             −8.47    3.6E-03
  *[Prrx2]{.ul}*                        −7.19              1.0E-01           *Isl1*       −4.08   3.6E-02   *Msx2*             −8.98    5.1E-03
  *[Asb12]{.ul}*                        −9.04              1.1E-01           *Ebf2*       −7.43   4.0E-02   *Id3*              −3.21    5.8E-03
  *[Cdc6]{.ul}*                         −1.75              1.3E-01           *Ebf1*       −5.39   4.3E-02   *Prrx2*            −10.99   6.9E-03
  *[Ncoa4]{.ul}*                        −1.48              1.4E-01           *Hey1*       −4.69   4.4E-02   *Prss35*           −5.99    1.8E-02
  *[Krr1]{.ul}*                         −1.47              1.4E-01           *Epas1*      −3.42   4.6E-02   *Grhl3*            −6.02    2.6E-02
  *[Alx4]{.ul}*                         −5.93              1.5E-01           *Rarb*       −3.81   5.2E-02   *Foxd1*            −10.54   2.8E-02
  *[Wt1]{.ul}*                          −4.76              2.0E-01           *Hoxd9*      −7.63   5.5E-02   *Ripk4*            −9.34    3.0E-02
  *[Rhox2e]{.ul}*                       −3.29              2.0E-01           *Sox17*      −5.00   5.7E-02   *Ebf2*             −8.08    3.0E-02
  *[Pax8]{.ul}*                         −8.85              2.1E-01           *Creb3l1*    −4.59   5.8E-02   *Foxp2*            −3.93    3.4E-02
  *[Rhox6]{.ul}*                        −3.59              2.2E-01           *Ugp2*       −1.79   6.5E-02   *Zim1*             −7.30    3.4E-02
  *[Neurod6]{.ul}*                      −6.02              2.2E-01           *Nr3c1*      −2.93   6.9E-02   *Creb3l1*          −5.25    3.5E-02
  *[Hoxc4]{.ul}*                        −8.73              2.3E-01           *Notch4*     −4.21   7.1E-02   *Hoxd9*            −8.66    3.6E-02
  *[Rhox9]{.ul}*                        −3.68              2.3E-01           *Myt1*       −6.02   7.6E-02   *Sall4*            −2.66    3.8E-02
  *[Six1]{.ul}*                         −7.30              2.3E-01           *Elf3*       −6.86   7.6E-02   *Id2*              −2.69    3.9E-02
  *[Tcf21]{.ul}*                        −5.63              2.3E-01           *Ankrd1*     −4.84   7.7E-02   *Hoxc10*           −5.83    5.0E-02
  *[Runx1t1]{.ul}*                      −1.79              2.4E-01           *Onecut3*    −8.32   8.3E-02   *Myt1*             −6.64    6.7E-02
  *[Klf1]{.ul}*                         −6.56              2.6E-01           *Hivep3*     −5.19   8.4E-02   *Elf3*             −7.56    6.9E-02
  *[Aff3]{.ul}*                         −3.18              3.1E-01           *Zfp36l1*    −1.90   8.6E-02   *Isl1*             −3.79    7.0E-02

(A and B) Top 25 up-regulated TFs (A) and top 25 down-regulated TFs (B) in HEC versus EC, HSC versus HEC, and HSC versus EC comparisons. FDR, FDR corrected p-value; logFC, log fold change. All genes with FDR \< 0.05 except genes with underlining.

In the HSC fraction, many TFs with known roles in HSC development, including *Etv6*, *Gfi1*, *Gfi1b*, *Myb*, *Myc*, *Hlf*, *Meis1*, *Hhex*, *Runx1*, *Mpl*, and *Ikzf1* and *2* ([Table 1](#tbl1){ref-type="table"} and Table S4), were found to be significantly up-regulated as compared with ECs or HECs. We identified several novel TFs not previously reported to be involved in embryonic HSC generation such as zinc-finger proteins *Zfp106*, *Zfp445*, *Zfp748*, and *Zfp763*, megakaryocyte factor *Nfe2*, transcriptional corepressor *Bcor*, and *Cbfa2t3* (*Eto2*). Also present in the top hits were chromatin-remodeling factors *Suz12*, *Paxip1*, *Kdm5a*, *Smarca4* (*Brg1*), *Ezh1*, *Bptf*, and *Hdac1* and de novo DNA methylation genes *Dnmt3a*/*Dnmt3b* and *Dnmt1*. The down-regulation of several *Hox*, *Tbx*, and *Fox* genes was observed in the EC to HEC and HEC to HSC transition, whereas only *Hoxa9*, *Hhex*, and *Foxk1* were up-regulated in HSCs as compared with ECs or HECs (Table S4).

It has been shown that a pivotal (heptad) group of TFs work together in transcriptional regulatory complexes to regulate the expression of downstream target genes in hematopoietic progenitor cell lines ([@bib52]). The heptad TFs could act as one of the transcriptional hubs for the regulation of EHT. Our RNAseq datasets reveal that all heptad TFs increase during EHT ([Fig. 5 A](#fig5){ref-type="fig"}). To identify genes encoding novel EHT and embryonic HSC surface markers, the 530 DEGs were compared with the 927 heptad TF targets identified by chromatin immunoprecipitation (ChIP)seq analyses in HPC7 cells. 58 DEGs were found to be targets of heptad TFs, with *CD34* and *Gpr56* as the top hits ([Fig. 5, B and C](#fig5){ref-type="fig"}). Interestingly, also in the whole transcriptome analysis of EHT, *Gpr56* was identified as the top differentially expressed receptor gene in the HEC to HSC transition, followed by *cKit* ([Fig. 4 B](#fig4){ref-type="fig"}). Because both CD34 and cKit function has been studied in HSCs and these markers are used extensively for HSC isolation ([@bib44]), we focused on Gpr56.

![***Gpr56* is a heptad target in mouse and human blood progenitors.** (A) Mean FPKM values of heptad factors in EC, HEC, and HSC fractions. (B) A Venn diagram showing the overlap between sites with combinatorial binding of Scl, Gata2, Runx1, Erg, Fli1, Lyl1, and Lmo2 in HPC7 cells (Heptad targets) and 530 DEGs during EHT. (C) Heat map of top 10 heptad target DEGs based on highest expression in HSCs and with respective mean FPKM values inside heat map. (D) qPCR for TF enrichment at *Gpr56-37* as compared with IgG and control in HPC7 mouse myeloid progenitor cells (*n* = 4). (E) Transfection assays in 416B and HPC7 mouse progenitors show enhancer activity of *Gpr56-37* (*n* = 3). (F) Transactivation assays in Cos7 cells showing synergistic responsiveness of the *Gpr56-37* element to Runx1, Gata2, and Fli1 (*n* = 4). (D--F) Error bars show SD. (G) TF binding at Hs*GPR56-48* (corresponding region to Mm*Gpr56-37*) in primary human CD34 HSCs.](JEM_20140767_Fig5){#fig5}

The *Gpr56* heptad consensus region in the mouse is located 37 kb upstream of the translational start site. We identified this region as the *Gpr56-37* enhancer. Enrichment of heptad factors at the *Gpr56-37* element was found in mouse HPC7 cell line by quantitative PCR (qPCR; [Fig. 5 D](#fig5){ref-type="fig"}). Transactivation assays in hematopoietic progenitor cell lines showed significant activation of *Gpr56-37* enhancer, whereas overexpression of three of the heptad factors (Gata2, Runx1, and Fli1) showed synergistic activation of the *Gpr56-37* enhancer ([Fig. 5, E and F](#fig5){ref-type="fig"}). Moreover, we identified a homologous element 48 kb upstream of the human *GPR56* gene. In human CD34^+^ HSC-enriched cells, we found binding of all seven heptad TFs to the human *GPR56-48* element ([Fig. 5 G](#fig5){ref-type="fig"}; [@bib6]). These data suggest that the heptad TFs and their downstream target *Gpr56* are important in HSC generation during EHT, as well as in healthy and leukemic human HCs. Because nothing is known concerning Gpr56 in embryonic hematopoietic development, we examined its regulation and role during EHT.

Gpr56 is required during EHT for HSC generation
-----------------------------------------------

To confirm localized expression of *Gpr56* in cells undergoing EHT, we performed in situ hybridization (ISH) analysis of the E10.5 AGM. High-level *Gpr56* expression was observed in some aortic HCs ([Fig. 6 A](#fig6){ref-type="fig"}), and no/low expression was observed in aortic ECs. An overlap of *Gpr56* expression with some GFP^+^ HCs was found by ISH of *Ly6aGFP* E10.5 AGM sections ([Fig. 6 B](#fig6){ref-type="fig"}). Thus, the localized expression of *Gpr56* is consistent with FPKM values derived from RNAseq datasets and strongly suggests a role in HSC generation.

![**In silico and in vivo analysis of *Gpr56*.** (A) ISH of WT mouse E10.5 AGM sections shows specific expression of *Gpr56* in some HCs, a few cells lining the aorta (Ao), and the notochord (NT). The top images show low magnification of AGM cross-section, and the bottom images show high magnification of the boxed areas. (B) ISH of E10.5 *Ly6aGFP* AGM shows coexpression of GFP and *Gpr56* in some HCs. (C) Homology relationships of the *Gpr56* coding sequence of different vertebrate species. (D--F) Analysis of WT and *gpr56* MO zebrafish for the presence of HSCs. (D) ISH with the HSC marker *cmyb* at 30 hpf. (E) Fluorescent analysis of WT and MO-injected CD41:GFP transgenic embryos at 48 hpf. Numbers in the panels indicate the number of embryos with the depicted phenotype. Arrowheads (left) indicate CD41-expressing HCs in the aorta. The dashed lines (right) indicate the outline of the morphant zebrafish embryo for orientation purposes. (F) ISH with arterial cell marker *grl*. No vascular or developmental abnormalities can be observed in *gpr56* morphant embryos. (G) HSC rescue of *gpr56* morphant zebrafish with *gpr56* RNA (zebrafish and mouse) as shown by ISH for *cmyb*. Ectopic *cmyb* expression in the posterior cardinal vein is clearly visible. No vascular abnormalities can be observed by *grl* ISH. (D and G) Insets show boxed areas at higher magnification. Bars: (A) 30 µm; (B) 10 µm; (D--G) 100 µm. (H) Effect of human GPR56 activity in neutrophil differentiation of the 32D-CSF3R unipotent stem cell line. 32D-CSF3R cells cultured in medium containing CSF3 efficiently differentiated into neutrophils. Only constitutive active mutant GPR56 (MUT) could block differentiation. Diff ct, differential count; Cntl, empty vector control; WT, WT human GPR56 vector; mut, constitutively active human GPR56 mutant vector; Bl, blast morphology; In, intermediate morphology; Ne, neutrophil morphology.](JEM_20140767_Fig6){#fig6}

*Gpr56* is highly conserved across different vertebrate species (mean multiple sequencing alignment score = 85%; [Fig. 6 C](#fig6){ref-type="fig"}). To validate the involvement of *Gpr56* in HSC generation, we used a zebrafish morpholino oligo (MO) knockdown approach. At 30 and 48 h post fertilization (hpf), morphants were assayed by ISH (30 hpf) for *cmyb*, a marker for emerging HSCs ([@bib17]). WT embryos show *cmyb*-expressing cells along the aorta ([Fig. 6 D](#fig6){ref-type="fig"}). In contrast, *cmyb*-expressing cells are severely reduced in *gpr56* MO--injected embryos. To validate that this was a defect in HSC generation, we injected the *gpr56* MO into CD41-GFP transgenic embryos (CD41 marks HCs; [@bib23]; [@bib17]; [@bib41]). The number of CD41-GFP^+^ cells in the caudal hematopoietic tissue at 48 hpf is significantly decreased from 36.7 ± 4.0 cells in WT to 12.5 ± 1.8 in *gpr56* morphants ([Fig. 6 E](#fig6){ref-type="fig"}), suggesting that Gpr56 is important for the emergence of HSCs. No abnormalities in embryo growth or the structure of the vasculature/aorta were found by ISH for arterial endothelial marker *gridlock* (*grl*; [Fig. 6 F](#fig6){ref-type="fig"}; [@bib56]). To test whether the *gpr56* MO does not show an off-target effect, we performed rescue experiments by injecting *gpr56* mRNA. *Gpr56* morphants could be rescued with zebrafish *gpr56* mRNA, as well as with a mouse *Gpr56* mRNA to yield full restoration of aortic *cmyb* expression ([Fig. 6 G](#fig6){ref-type="fig"}). Interestingly, some ectopic expression of *cmyb* is observed in the region ventral to the aorta. These data indicate that *gpr56* is an essential player in the HSC generation program and that its functional domains are maintained between mouse and zebrafish. Ectopic generation of phenotypic HSCs in zebrafish by Gpr56 overexpression further highlights the unexpected function of this molecule in induction of HSC generation.

To further study the function of Gpr56 in HSCs, we used the 32D-CSF3R cell line, a unipotent mouse stem cell differentiation model in which colony-stimulating factor-3 stimulates their differentiation to neutrophils. ([Fig. 6 H](#fig6){ref-type="fig"}). When stimulated with CSF3, cells transduced with an empty vector or WT human *GPR56* vector lost their blast characteristics and differentiated. However, cells transduced with constitutively active (MUT) human *GPR56* resulted in an increase in blast-like cells and in significantly fewer differentiated cells (eight- to fourfold fewer), suggesting that GPR56 is also essential for the maintenance of an undifferentiated cell state.

DISCUSSION
==========

RNA sequencing analyses of EHT and developing HSCs provide a new perspective on the molecules and processes. Whereas previous methods of transcriptome analysis have identified many of the obvious regulators of hematopoietic development, this method provides an accurate accounting of all expressed genes and also small gene expression level changes between the rare, relevant cell types. We have shown here that HECs (the precursors of the earliest emerging HSCs in the midgestation mouse aorta), as distinguished from other ECs by Ly6aGFP expression, have closely related but distinct transcriptional programs. Comparisons between ECs and HECs reveal a developing program indicative of cell migration and changing cell morphology in HECs, while they retain an angiogenic program. The up-regulation of the HSC hematopoiesis program begins in HECs, further distinguishing them from ECs. Of the 530 DEGs, important receptors and TF genes were identified, including *Gpr56*, which is required for HSC formation. Moreover, the heptad (hematopoietic) TFs were found to be up-regulated during EHT. These factors bind the *Gpr56* enhancer and regulate its expression, thus providing a proof of principle for in silico bioinformatical predictions of the combinatory role of the heptad TFs in the emergence of HSCs during EHT. Thus, our datasets are predictive of functionally relevant EHT genes and processes.

RNAseq analysis of small numbers of physiologically relevant cells
------------------------------------------------------------------

The *Ly6aGFP* transgenic marker in combination with CD31 and c-Kit cell surface markers allowed the high enrichment of HSCs, HECs, and ECs isolated from the aorta at the developmental time when HSCs begin to emerge. Imaging experiments verified the correlation between these markers, the expected cell type, and localization within the AGM region. Moreover, we confirmed that functional adult-repopulating HSCs are exclusively contained within the HSC fraction (0.002% of AGM cells) and that both endothelial fractions (ECs and HECs) do not contain hematopoietic progenitors or HSCs. Thus, the Ly6aGFP marker currently allows the highest level of enrichment for HECs (Fig. S1 B) that will undergo transition to HSCs, as compared with previously used markers.

Previous comparative HSC gene expression profiling (microarray) studies identified several new regulators of AGM HSCs, but the genetic program of HECs was not examined ([@bib26]; [@bib29]). During preparation of this manuscript, a new microarray study of EHT-relevant populations was performed based on cells expressing the *Runx1+23*-enhancer marker ([@bib46]). Runx1+23GFP marks 68% of VE-cadherin^+^ (endothelial and hematopoietic) cells at E8.5, marking many HECs that are not as yet exhibiting EHT. However, Ly6aGFP expression marks only a small fraction (13--19%) of CD31^+^ aortic cells and is probably more specifically marking the active HECs at E10.5.

Given the limited number of cells in our enriched aortic EC, HEC, and emerging HSC fractions, RNA sequencing provides the most efficient and sensitive method for analysis of EHT-relevant cells. Only 4--14 embryos (aortas) were used per sequencing experiment to isolate sufficient quantities of total RNA from sorted cell populations. With as few as 593 sorted cells, we successfully applied RNAseq technology with the SMARTER protocol, recently shown to be the best RNAseq method for low numbers of cells ([@bib4]). Additionally, RNAseq analysis has the great advantage over microarrays in not only providing the whole transcriptome, but also revealing isoform-specific transcripts in the sequenced samples. For example, *Gpr56* expresses two transcript variants. We found variant 1 (GenBank accession no. [NM_001198894](NM_001198894)) of *Gpr56* to be expressed exclusively in HSCs, whereas variant 2 (GenBank accession no. [NM_018882](NM_018882)) was expressed in ECs, HECs, and HSCs. Variant 2 was more highly represented in HSCs (FPKM = 323) as compared with variant 1 (FPKM = 52).

Identification of processes involved in EHT
-------------------------------------------

For the first time, datasets from aortic ECs, HECs, and HSCs provide an overview of the general processes involved during EHT. Quantitative levels of gene expression between EHT-enriched cell fractions show only a small number of significant DEGs: 139 between HECs versus ECs and 340 between HSCs versus HECs. Not surprisingly, the genes with high expression in midgestation aortic ECs are mainly those involved in "general developmental processes." These and other GO categories related to cell migration and focal adhesion are highly represented in HECs, highlighting the fact that HECs must change their adhesive properties to bulge out of endothelial lining of the aorta, undergo morphological changes as they become HCs, adhere to other HCs within the clusters, and take on hematopoietic identity and function. GO analysis of DEGs with the highest expression in HSCs shows enrichment of "hematopoiesis" and "positive regulation of histone methylation" terms.

HECs are a transcriptionally dynamic cell type at the interface of EHT. Concurrent with the initiation of the hematopoietic program and HC formation, hematopoietic genes become activated in HECs, whereas endothelium-specific cell adhesion molecules and TFs are down-regulated in HSCs. Our RNAseq data are in agreement with the recent single-cell high-throughput qPCR analysis results for 18 known endothelial and hematopoietic genes during EHT (Fig. S2 D; [@bib46]). We also identified several genes involved in angiogenesis by selection for GO term "receptor activity" in HEC versus EC comparisons ([Fig. 4 A](#fig4){ref-type="fig"}). These include *Plxnd1*, *Eltd1*, *Calcrl*, *Ramp2*, and *S1pr1*; *Plxnd1* and *Eltd1* are both induced by VEGF ([@bib19]; [@bib27]). *Calcrl*, a GPCR, induces angiogenesis upon association with Ramp2 and Kdr/Vegf-r2, both of which are significantly induced in HECs ([@bib13]). Collectively, these findings suggest a role for angiogenesis-related receptors in activation of hematopoietic potential and generation of HECs.

GPR56: a novel EHT regulator
----------------------------

*Gpr56*, one of the top hits in our HSC versus HEC comparison (30-fold increase) and bound by all heptad TFs, is indeed a novel regulator for emerging HSCs in the embryonic vasculature. Contrary to expectations raised by the lack of HSC defects in mouse *Gpr56* KO embryos (generated by deletion of the first two exons \[[@bib43]\]), our RNAseq data suggested a strong role for Gpr56 in emergence of HSCs. In the E10.5 mouse aorta, we localized *Gpr56* expression to a few HCs/HSCs (Ly6aGFP^+^). Upon *gpr56* knockdown, zebrafish embryos showed severe reduction in HSCs (*cmyb*) and CD41^+^ hematopoietic stem/progenitor cells, revealing a requirement for Gpr56 in HSC generation. Our rescue experiments in *gpr56* morphants show that both zebrafish and mouse *Gpr56* RNA can restore aortic hematopoietic stem/progenitor generation. Moreover, *Gpr56* overexpression resulted in ectopic hematopoietic progenitor/stem cell formation in the axial vein, suggesting that the Gpr56 signaling axis may be useful for inducing new HSCs.

We propose that the lack of embryonic lethality in *Gpr56* KO embryos could be the result of redundancy by other GPCRs or residual Gpr56 activity in the mouse transgenic model. Our RNAseq and RT-qPCR validation (Fig. S2 E) data show an increase in the expression of *Gpr114* (77 kb upstream of *Gpr56*) and *Gpr97* (48 kb downstream) during EHT. The ligand binding N-terminal part of Gpr114 has 47% amino acid similarity (and 27% identity) with Gpr56. *Gpr114* is present only in mammals. Also, assays testing a human *Gpr56* variant missing a large part of the second exon and the complete third exon showed that it partially retains the ability to activate *SRE*, *E2F*, *NFAT*, and *iNOS* promoters ([@bib18]). Thus, Gpr56 is an unexpected novel EHT regulator essential for HSC generation and maintenance, and its function is conserved between mouse and zebrafish.

How Gpr56 acts in HECs as they transdifferentiate to HSCs is unknown, but it could affect physical properties such as adherence, cluster formation, signal transduction, migration, and/or self-renewal. Some of these features are consistent with findings in neuronal stem cells, BM HSCs, and leukemic cells, in which it has been proposed that Gpr56 functions in cell adhesion, migration, and/or repression of apoptosis ([@bib14]; [@bib43]). We found that Gpr56 functions in the maintenance of the undifferentiated state of a unipotential HSC line. The conservation of Gpr56 across species will allow for future high-throughput study of the mechanism by which Gpr56 affects EHT and generation of HSCs.

Our results on heptad TF binding to the Gpr56 enhancer suggest that other heptad targets in the overlapping list are likely to be relevant in EHT. However, not all genes that we identified as highly up-regulated during EHT are targets of the heptad complex, for example *cKit*. Because EHT regulation is likely to be multilayered, we are using our whole transcriptome dataset as a resource to identify other candidate transcriptional hubs.

In summary, novel and known EC, HEC, and HSC genes were identified in our RNAseq datasets. These comparative quantitative data have high predictive value for identifying functionally important molecules that direct the cellular processes involved in EHT and could instruct methods for de novo HSC generation either by direct somatic cell conversion or pluripotent stem cell differentiation.

MATERIALS AND METHODS
=====================

### Cell preparation and flow cytometry.

*Ly6aGFP* and WT mouse embryos were dissected as described previously ([@bib40]), and single cells were prepared by collagenase treatment (0.125%, 45 min, 37°C) and washed with PBS, 10% heat-inactivated FCS, and 1% penicillin/streptomycin (PS). Cells were stained with RαMCD31-AF647 (1:400; BioLegend) and RαMcKit-PE (1:1,200; BD) for 30 min at 4°C, washed with PBS/10% FCS/1% PS, and analyzed/sorted on a FACSAria III or SORP FACSAria II (BD).

### Mouse embryo immunostaining and imaging.

10-µm cryosections were prepared as described in [@bib24]; except last dehydration steps were omitted), stained with RαMCD34-biotin (1:100; BD) and Streptavidin-Cy5 (1:500; Jackson ImmunoResearch Laboratories, Inc.), and imaged on an SP5 confocal microscope (Leica).

Whole-mount embryos were prepared as described previously ([@bib54]), stained with RαM-cKit (1:500; eBioscience) and αRat--Alexa Fluor 647 (1:5,000; Invitrogen), RαMCD31-biotin (1:500; BD) and Streptavidin--Alexa Fluor 555 (1:500; Invitrogen), RαGFP (1:2,000; MBL) and GαR--Alexa Fluor 488 (1:1,000; Invitrogen), and imaged on an SP5 microscope. 1.48 µm between stacks; 17 stacks (23.7 µm) merged.

For ISH, embryos (36 sp) were fixed and rotated overnight, 4°C in 4% paraformaldehyde, washed three times in PBS at 4°C, and embedded in paraffin, followed by overnight ethanol dehydration and two xylene washes using a Histokinette (Microm HMP110). 10-µm sections were obtained using a microtome. For *Gpr56* cRNA probes, the mouse coding sequence (942 bp) was primed from BM cDNA with FW 5′-TTGCAGCAGCTTAGCAGGTA-3′ and RV 5′-GATAGCCGGGCACATAGGTA-3′ oligos, and the fragment was ligated to pGEM-T Easy (Promega) and linearized before sense and α-sense probes synthesis: overnight at room temperature with DIG-dUTP mix (Roche) and SP6/T7 polymerases (Roche). Hybridization was performed as described previously ([@bib9]), without incubation in H~2~O~2~. After developing color for several days, sections were washed five times for 30 min in PBS-0.1% Tween (Tw) and mounted in Kaiser's Glycerol gelatin (Merck). *Ly6aGFP* sections were incubated overnight at room temperature with rabbit polyclonal anti-GFP (1:1,000; Abcam) in PBS^Block^ (1% BSA, 0.05% Tw), washed in PBS^+^ (0.05% Tw), and incubated for 30 min at room temperature with polyclonal biotinylated GantiRIg (1:400; Dako) in PBS^Block^, washed, incubated for 30 min at room temperature with Streptavidin-HRP (PK-7100; Vector Laboratories), washed, and color developed at room temperature in the dark by 6-min incubation in 4 ml of 5% (wt/vol) diaminobenzidine (Fluka) and 200 ml PBS. 70 µl of 35% H~2~O~2~ was added to start the reaction. Slides were rinsed with tap water, mounted, and imaged on a BX40F4 microscope and Colorview IIIu camera (Olympus). Sense control probes showed no signal.

### Hematopoietic assays.

Sorted cells were plated in triplicate in methylcellulose (MethoCult GF; STEMCELL Technologies) with 1% PS and incubated at 37°C, 5% CO~2~ for 12 d. Hematopoietic colony types were distinguished by morphology and counted with an inverted microscope.

For all transplantations, 9-Gy irradiated (split dose) C57BL/6 female recipients were used. 2 × 10^5^ C57BL/6 spleen cells were coinjected with the sorted cell samples. Chimerism in hematopoietic tissues was assessed by semi-qPCR for the *GFP* transgene (eGFP FW 5′-AAACGGCCACAAGTTCAGCG-3′ and RV 5′-GGCGGATCTTGAAGTTCACC-3′), normalized to myogenin (Myo FW 5′-TTACGTCCATCGTGGACAGC-3′ and RV 5′-TGGGCTGGGTGTTTAGTCTTA-3′). Control mixes of *Ly6aGFP* and WT DNA were used to make a standard curve, and the trend line formula was used to calculate the percentage of reconstitution of each sample. Peripheral blood cell donor chimerism was assayed at 1 and 4 mo after injection, and mice were sacrificed for analysis of donor chimerism in all hematopoietic tissues. Recipients considered reconstituted are ≥10% donor chimerism positive. All experiments have been conducted according to Dutch law and have been approved by the animal experiments committee (Stichting DEC consult, Dier Experimenten commissie, protocol numbers 138-11-01 and 138-12-13).

### RNA isolation.

Cells (see Table S1) were directly sorted into PBS/10% FCS/1% PS and centrifuged, and supernatant was removed. Cells were lysed, and RNA was isolated using the *mir*Vana miRNA Isolation kit (Ambion) according to the manufacturer's protocol. RNA quality and quantity were measured by the 2100 Bioanalyzer (Agilent Technologies).

### mRNA sequencing analysis.

RNA samples (Table S1) were prepared by SMARTer protocol. Illumina TrueSeq v2 protocol was used on HiSeq2000 with single read of 36 bp + 7 bp index. Reads were aligned to the mouse genome (NCBI37/mm9) using Tophat/Bowtie and mapped to the mouse genome (NCBI37/mm9), and the generated count table was analyzed by R/Bioconductor package edgeR according to [@bib28]. Counts were normalized for mRNA abundance, and differential expression analysis was performed using edgeR ([Fig. 2 A](#fig2){ref-type="fig"}). B-H method was used for p-value correction with an FDR of 0.05 as statistically significant. Variance stabilized counts were calculated by R/Bioconductor package "DESeq" for all the genes ([@bib1]). Heat maps were generated from the log-scaled variance stabilized counts of DEGs. GSEA was performed using the preranked option in combination with log fold change values of each comparison calculated by edgeR. Cufflinks was used to compute transcript abundance estimates in FPKMs ([@bib48]). For DEGs, the FPKMs for each gene across all samples were normalized by division with maximum FPKM observed for that gene. Patterns were generated based on normalized FPKM, with expression levels lower than 1/3 assigned as low (L), between 1/3 and 2/3 as intermediate (I), and more than 2/3 as high (H). Patterns were then categorized as ECs, HECs, or HSCs. Genes corresponding to EC, HEC or HSC patterns were separately used for GO, KEGG, and Phenotype ontology enrichment analysis using the WebGestalt web application ([@bib50]). GO terms were summarized using the REVIGO tool ([@bib45]).

### Cell lines.

CHOK3 cells transfected with an expression vector for the mouse SCF gene were grown initially in DMEM (Gibco) until they became confluent. They were then grown in Stem Cell Pro media (Gibco) supplemented with 1% PS, [l]{.smallcaps}-glutamine, and 0.5% FBS. HPC-7 mouse hematopoietic progenitor cells were grown in IMDM (Gibco) supplemented with 10% CHOK3 conditioned media, 1% PS, 10% FBS, and 1.5 × 10^−4^ monothioglycerol. See [@bib21] and [@bib52] for details.

### ChIP.

ChIP assays were performed in HPC-7 cells. 2 × 10^7^ cells per antibody were treated with 0.4% formaldehyde, and cross-linked chromatin was sonicated to fragments of 300--500 bp. Cross-linked, sonicated chromatin was distributed evenly for immunoprecipitation. SYBR Green RT-PCR was performed on a Stratagene Mx3000p and analyzed using the MxPro software. Relative enrichment levels were calculated by normalizing results to the IgG control. For details see [@bib21]. CD34 and HPC7 ChIPseq data were downloaded from the BloodChIP database ([@bib2]; [@bib6]) and from [@bib52].

### Luciferase and LacZ assays.

Transfection was performed by electroporation of 5--10 × 10^6^ cells with 10 µg vector DNA using a GenePulser Excell (Bio-Rad Laboratories). The luciferase assay was performed using a modified version of the Dual-Luciferase Reporter Assay System (Promega). Transient transfections were cotransfected with the pEFBOS-LacZ vector, and luciferase data were normalized to the lacZ data. For stable transfection assays, cells were cotransfected with pGK Neo and resistant cells were used for luciferase assays as described in [@bib21].

### Transactivation.

Cos7 cells were cultured in 6-well plates (5 × 10^5^ cells/well) overnight. *Runx1.pcDNA3*, *CBFb.pcDNA3*, *Fli1.pcDNA3*, and *Gata2.pMSCV-PIG* or empty vectors were transfected along with the pEFBOS-*lacZ* control vector and the *Gpr56-37*.pGL2prom enhancer construct in varying combinations (0.5 µg DNA/well) using the ProFection Mammalian Transfection system (Promega). After 48 h, luciferase and *lacZ* assays were performed as detailed in [@bib21].

### Zebrafish.

Zebrafish (*Danio rerio*) embryos were raised at 28.5°C ([@bib51]). Heterozygous *-6.0itga2b:EGFP* embryos (CD41-GFP; [@bib23]) were maintained by crosses with WT zebrafish. For ISH 0.003% 1-phenyl-2-thiourea (PTU)--treated embryos (30 hpf) were fixed over night with 4% PFA in PBS containing 3% sucrose, transferred to MeOH, hybridized with a *cmyb* probe (gift of R. Patient, University of Oxford, Oxford, England, UK) according to [@bib8], and imaged with BX40 (Olympus) and AX10 (Carl Zeiss) fluorescent microscopes with an AxioCam MRm camera (Carl Zeiss).

### Human GPR56 expression constructs and differentiation of 32D/G-CSF-R cells.

WT *hGPR56* and truncated constitutively active *hGPR56* (as described by [@bib37]) were amplified, and a Kozak sequence and two N-terminal flag tags were added. The WT and constitutively active *hGPR56* (*wtGPR56/caGPR56*) were subcloned into *pEGFPN1* to generate an eGFP fusion protein. The *wt/caGPR56-eGFP* fusion inserts were PCR amplified and cloned into the *pLNCX2* retroviral vector (Takara Bio Inc.).

The 32D/G-CSF receptor (32D/G-CSF-R) cell line was cultured at a density \<10^6^ cells/ml in RPMI 1640 medium (Life Technologies), supplemented with 1% PS, 10% FCS, and 10 ng/ml mouse IL-3 (CHO conditioned). 10^6^ cells were transduced (RetroNectin; Takara Bio Inc.) with *pLNCX2-EGFP*, *pLNCX2-wtGPR56-EGFP*, or *pLNCX2-caGPR56-EGFP* and selected in 0.8 mg/ml G418 (Life Technologies) 2 d after infection (efficiency 100% at day 4). For the differentiation assay, cells were washed twice in HBSS (Life Technologies), cultured in the same medium, except mIL3 was replaced with 10 ng/ml human CSF3 (Amgen), and placed in 6-well plates (2 × 10^5^ cells/ml). Cell density was adjusted to 2 × 10^5^ cells/ml on a daily basis. Morphology was determined by microscopy on May-Grünwald-Giemsa--stained cytospins at day 7 and scored based on phenotype (blast, intermediate, neutrophil, \>100 cells).

### Primers.

For cloning: Gpr56-37F, 5′-GAGGATCCTCCATGAGGGACATCTTCAA-3′; Gpr56-37R, 5′-AGTCGACACGGGCTTATCACGAGAAAT-3′. For ChIP-qPCR: Gpr56-37F, 5′-AATGTTATCAACCGTCTGC-3′; Gpr56-37R, 5′-CCTCACCTAATCAAGATATGTC-3′. For RT-qPCR validations: Gpr56 FW, 5′-GCAGAACACCAAAGTCACCA-3′; Gpr56 RV, 5′-TGTCTCTGCTCACTGTCTCG-3′; Gpr97 FW, 5′-CTGGGATATGGCTAAAGGAGAC-3′; Gpr97 RV, 5′-AAGGCGAAGAAGGTCAAGTG-3′; Gpr114 FW, 5′-TCACTGCTCAATAACTATGTCC-3′; Gpr114 RV, 5′-ACTGTATACCCTTCCAGACTC-3′; Ikzf2 FW, 5′-AGCCCTTCAAATGTCCTTTCTG-3′; Ikzf2 RV, 5′-CAGCGTTCCTTGTGTTCCTC-3′; Meis1 FW, 5′-CATCTTTCCCAAAGTAGCCAC-3′; Meis1 RV, 5′-GTAAGTCCTGTATCTTGTGCC-3′; Mpl FW, 5′-TTGGACTTCAGTGCTTTACCT-3′; Mpl RV, 5′-CTCCTCTTCACATTTCTCCCA-3′; Mycn FW, 5′-GGAGAGGATACCTTGAGCGA-3′; Mycn RV, 5′-GGTTACCGCCTTGTTGTTAGAG-3′; Gata2 FW, 5′-CACCCCTAAGCAGAGAAGCAA-3′; Gata2 RV, 5′-TGGCACCACAGTTGACACACT-3′; Gata3 FW, 5′-TGTGGGCTGTACTACAAGCT-3′; Gata3 RV, 5′-TCGATTTGCTAGACATCTTCCG-3′; Runx1 FW, 5′-CAGGTAGCGAGATTCAACGA-3′; Runx1 RV, 5′-TTTGATGGCTCTATGGTAGGTG-3′; Hlf FW, 5′-CGCAAAGTCTTCATTCCCGA-3′; Hlf RV, 5′-GCTCCTTCCTTAAATCAGCCA-3′; Gapdh FW, 5′-GACTTCAACAGCAACTCCCA-3′; Gapdh RV, 5′-GCCGTATTCATTGTCATACCAG-3′.

### Online supplemental material.

Fig. S1 provides FACS characterization of CD31^+^ AGM cells and a representative multilineage repopulation analysis of transplanted mice. Further details of RNAseq analyses and a comparison with the published single-cell qPCR analysis of EHT cells ([@bib46]) and adult BM HSCs ([@bib39]) is provided in Fig. S2. Table S1 contains details of the material used for RNAseq analysis. Table S2 contains the 530 DEGs and their expression patterns and groupings. Ontology enrichment analysis results for each group are provided in Table S3. Table S4 contains a list of up- and down-regulated TFs as found by differential expression analysis with edgeR. All sequencing data has been uploaded to GEO repository under accession number [GSE63316](GSE63316). Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20140767/DC1>.
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